Study on the Effectiveness of Low-Dose Mifepristone for Managing Uterine Fibroids in Women in Goa, India

Low-Dose Mifepristone in Fibroid Management: A Single-Center Prospective Study in Goa, India - NILL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/01/079068

Enrollment

100

Registered

2025-01-20

Start date

Unknown

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O998- Other specified diseases and conditions complicating pregnancy, childbirth and the puerperium

Interventions

Intervention1: Mifepristone drug: NAME OF MEDICATION-Mifepristone DOSAGE-Tablet ROUTE-Oral DOSE-25mg FREQUENCY-Once a day for 3 months Control Intervention1: NA: NA

Eligibility

Inclusion criteria

Inclusion criteria: Females of reproductive age group 18 to 49 years with symptomatic fibroids sized more than 3cm and less than 8cm Women with Pictorial Blood Loss Assessment Chart PBAC more than 100 Women diagnosed with uterine fibroid

Exclusion criteria

Exclusion criteria: Women allergic to mifepristone Pregnant or lactating mothers Women with a history of DVT/thromboembolism, liver dysfunction Those not consenting to be a part of the study

Design outcomes

Primary

Measure	Time frame
symptom relief menstrual changes PBACTimepoint: symptom relief 2 years menstrual changes PBAC 2 years	—

Secondary

Measure	Time frame
NATimepoint: NA	—

Countries

India

Contacts

Public ContactDr Rini Naik

Healthway Hospitals Pvt. Ltd.,

rininaik123@gmail.com9923645243

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026